According to reports from Business Standard, Transgene Biotek reported a consolidated net loss of ₹0.39 crore for the quarter ended June 2026, representing an improvement from the net loss of ₹0.43 crore recorded in the corresponding quarter of the previous financial year. The company's financial performance showed mixed results with revenue growth offsetting operational challenges.
As reported by Business Standard, Transgene Biotek's sales increased by 20.00% to ₹0.06 crore in Q1 FY27, compared to ₹0.05 crore in the same quarter of the previous financial year. This revenue growth indicates the company's ability to expand its business operations despite the ongoing challenges in achieving profitability.
According to the financial data reported by Business Standard, the company's operating profit margin (OPM) remained at -100% in both the current and previous quarters. The PBDT (Profit Before Depreciation and Tax) stood at -₹0.35 crore in Q1 FY27, showing an improvement from -₹0.38 crore in Q1 FY26. The PBT (Profit Before Tax) was -₹0.39 crore compared to -₹0.43 crore in the corresponding quarter of the previous year.
As reported by Business Standard, the company's financial results for the quarter ended June 2026 were announced on August 7, 2026. The narrowing of the net loss from ₹0.43 crore to ₹0.39 crore indicates some operational improvements despite the company still operating at a loss. The 9% improvement in net loss demonstrates the company's efforts to reduce its financial deficit compared to the same quarter in the previous financial year.
